VERACYTE, INC.
VCYT · XNASCIK 1384101fmd_02F2559HAYA159P944P6Y4B311Services · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2011 to Sep 30, 2026, 60 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 65 | 72 | 92 | 120 | 117 | 220 | 297 | 361 | 446 | 517 |
| Cost of revenue | 25 | 28 | 33 | 36 | – | – | – | – | – | – |
| Gross profit | 40 | 44 | 59 | 84 | – | – | 176 | 230 | 298 | 363 |
| Research and development | 15 | 14 | 15 | 15 | 17 | 30 | 41 | 57 | 69 | 71 |
| Selling, general and administrative | 52 | 55 | 65 | 83 | 89 | 181 | 171 | 188 | 206 | 211 |
| Total operating expenses | 94 | 98 | 114 | – | – | – | – | – | – | – |
| Operating income | (29) | (27) | (22) | (15) | (35) | (82) | (41) | (86) | 16 | 58 |
| Interest expense | 3 | 5 | 2 | 1 | 0 | – | – | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 0 | 0 | 1 | 3 | 0 | 0 | 5 | 9 | 10 | 10 |
| Income before taxes | (31) | (31) | (23) | (13) | (35) | (82) | (36) | (77) | 26 | 68 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | (6) | 0 | (2) | 2 | 2 |
| Net income from continuing operations | (31) | (31) | (23) | (13) | (35) | (76) | (37) | (74) | 24 | 66 |
| Net income | – | – | (23) | (13) | (35) | (76) | (37) | (74) | 24 | 66 |
| Net income to common shareholders | (31) | (31) | (23) | (13) | – | – | (37) | (74) | 24 | 66 |